Navigation Links
Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials

EO commented "I am delighted to report such positive results, which confirm the therapeutic and commercial potential of ACE393. This important outcome for ACE BioSciences validates our approach and preclinical work and keeps us on track to launch ACE393 in 2010. In September last year, we entered a collaborative development agreement with the US Naval Medical Research Center (NMRC) to progress ACE393 through Phase II clinical trials and we are about to initiate the first of these studies. These are exciting times for ACE BioSciences in a transformational year for the company."

72 healthy subjects participated in the trial which was undertaken at the Mediscis Phase I clinical unit in Poitiers, France. ACE BioSciences will continue to monitor those patients who received the vaccine at three monthly intervals to evaluate the longevity of the immune response. The full results of the study will be presented by Dr Michael Darsley, Chief Development Officer at ACE BioSciences at the Vaccines for Enteric Diseases Conference, held in Portugal on 25-27 April 2007.

TD is the most frequent health problem in travellers from industrialized countries visiting developing countries. Recent research undertaken by Beremans Ltd in the US and UK, indicates that an effective Campylobacter vaccine for Traveller's Diarrhoea might be purchased by over two million travellers per year and ACE BioSciences estimates that this annual global market would be worth _350 million. The company aims to claim a substantial share of the market by providing the first effective commercial Campylobacter vaccine that delivers good protection and low side effect risk.

Notes for Editors

About Travellers Diarrhoea

Campylobacter jejuni is a bacterium that is one of the main causes of travellers_ diarrhoea. In addition to the disruption it causes to business and holiday travellers, infection is a significant issue for the military and among the 140,000 US military perso
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
Post Your Comments:
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... Dec. 17, 2014  IGI Laboratories, Inc. (NYSE MKT: ... of its offering of $125 million aggregate principal amount ... The Notes were offered and sold only to qualified ... Act of 1933, as amended (the "Securities Act"). ... of 3.75% per year, payable semiannually in arrears on ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... Jan. 8, 2012  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today ... trial of its fully human monoclonal antibody against VEGF-C, ... The Phase 1 study will examine the safety ... with advanced solid tumours who have no other standard ...
... Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... founder and member of the Board of Directors, Wylie ... was a thoughtful leader with an incredible scientific mind ... by his terrific wit and disarming good nature.  He ...
Cached Medicine Technology:Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 2Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 3Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 4Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients 5
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... December 15, 2014 OutMarket , ... released “ Social Media Cheat Sheets ,” a guide ... that drives results on the top ten social media ... It helps drive awareness, engagement, and customer service. It ... to make an impact on new networks and weather ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, 2014 ... millions of American women who have migraine: The debilitating headaches ... no association between migraine and breast cancer risk," said lead ... Medical School. "There is no positive association, so there is ... either." About 18 percent of American women and 6 ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... Austin, TX (PRWEB) December 15, 2014 ... with offices in 26 countries in North and South ... begun accepting responses from industry participants for its 2015 ... survey in order to identify upcoming business and market ... industry respondents. , The survey targets areas including:, ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... risk of deaths from advanced prostate cancer is to catch// ... suggests that effective screening can prevent as much as 35% ... in men and is the second leading cause of death ... cancers are discovered when they have already spread to other ...
... clinical trials support the enhanced bioavailability// of CoQ10 delivered ... manufacturers of CoQ10 products. ,Increasing its bioavailability, ... and food makers to use lower dosages, therefore saving ... food-grade emulsifiers and solvents to trap water droplets in ...
... to be able to block the HIV virus from entering human ... major step forward in treatment of HIV. ,Scientist from ... fight against the AIDS virus. The research headed by Hiroaki Mitsuya ... States. The patients took 0.02 ounces of AK602 twice a day ...
... A study done by the researchers of Ohio State University ... your diet, you tend to prosper as well. ,The ... gain are quite strong among white female population of America. ... lost weight, but this is not particularly true for black ...
... infants with lung problem are often treated with inhaled nitric ... that this therapy does not reduce the chances of death ... of opinion that premature babies who weigh less than 1.5kgs ... are the part of a study. Inhaled nitric oxide therapy ...
... and can be a cause of Global warming//. ... World’ said: ,"Worldwide reduction of meat production in the pursuit ... carry fewer political unknowns than cutting our consumption of fossil ... and chicken burgers would do more for the environment. ...
Cached Medicine News:Health News:Screening For Prostate Cancer May Reduce Mortality Rate 2
LM-770 Projection Digital Lensmeter...
Autolensmeter with color 5.7 inch LCD screen and built in printer....
Autolensmeter with black/white monitor and no internal printer....
An ideal basic fundus fluorescein camera with quality enhancing features at a mid-range price point. The camera has 1.7x magnification at 60 degree and 2.5x at 40 degree....
Medicine Products: